DHG Pharmaceutical Joint Stock Company

As of June 30, 2026, DHG Pharmaceutical Joint Stock Company carries a market capitalization of 12.19T, placing it among publicly traded companies globally. Its enterprise value stands at 10.49T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

DHG Pharmaceutical Joint Stock Company's next confirmed earnings release is scheduled for December 2, 2026.

As of June 30, 2026, DHG Pharmaceutical Joint Stock Company has 130.75M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, DHG Pharmaceutical Joint Stock Company maintains a current ratio of 2.47, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, DHG Pharmaceutical Joint Stock Company recorded 126.24B in income tax expense.

As of the close on October 22, 2026, DHG Pharmaceutical Joint Stock Company's stock has declined approximately 16.27% over the past 52 weeks. The 50-day moving average sits at 91,984.00, while the 200-day moving average is 96,812.00.

As of June 30, 2026, DHG Pharmaceutical Joint Stock Company holds 1.73T in cash and equivalents against 32.56B in total debt, resulting in a net debt position of -181.91B. Total book value stands at 3.42T, with working capital of 2.23T providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

DHG Pharmaceutical Joint Stock Company's most recent stock split took place on May 26, 2017 with a 2:3 split ratio.